[96a5a0]: / output / allTrials / identified / NCT00953394_identified.json

Download this file

343 lines (343 with data), 14.0 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
{
"info": {
"nct_id": "NCT00953394",
"official_title": "Continuous 5-fluorouracil Infusion Plus Long Acting Octreotide in Advanced Well Differentiated Neuroendocrine Carcinomas. A Phase II Trial of the Piemonte Oncology Network.",
"inclusion_criteria": "* histological diagnosis of well-differentiated neuroendocrine carcinoma according to the World Health Organization (WHO) classification;\n* locally advanced or metastatic disease not amenable to surgery with radical intent;\n* at least one measurable target lesion;\n* radiological documentation of progressive disease;\n* ECOG performance status grade <=2;\n* life expectancy >12 weeks;\n* adequate bone marrow reserve;\n* adequate hepatic and renal function;\n* ability to comply with the protocol procedures (including geographic accessibility);\n* written informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* non-malignant systemic disease or conditions that precluded patients from receiving the study therapy;\n* second primary malignancies and previous systemic antineoplastic treatment including somatostatin analogues;\n* history of prior malignancy, excepted for cured non-melanoma skin cancer, and cured in situ cervical carcinoma.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* histological diagnosis of well-differentiated neuroendocrine carcinoma according to the World Health Organization (WHO) classification;",
"criterions": [
{
"exact_snippets": "histological diagnosis of well-differentiated neuroendocrine carcinoma according to the World Health Organization (WHO) classification",
"criterion": "well-differentiated neuroendocrine carcinoma",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
},
{
"requirement_type": "classification",
"expected_value": "World Health Organization (WHO)"
}
]
}
]
},
{
"line": "* locally advanced or metastatic disease not amenable to surgery with radical intent;",
"criterions": [
{
"exact_snippets": "locally advanced or metastatic disease",
"criterion": "disease stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
]
},
{
"exact_snippets": "not amenable to surgery with radical intent",
"criterion": "surgical eligibility",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": false
}
]
}
]
},
{
"line": "* at least one measurable target lesion;",
"criterions": [
{
"exact_snippets": "at least one measurable target lesion",
"criterion": "target lesion",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
},
{
"requirement_type": "measurability",
"expected_value": true
}
]
}
]
},
{
"line": "* radiological documentation of progressive disease;",
"criterions": [
{
"exact_snippets": "radiological documentation of progressive disease",
"criterion": "progressive disease",
"requirements": [
{
"requirement_type": "documentation",
"expected_value": "radiological"
}
]
}
]
},
{
"line": "* ECOG performance status grade <=2;",
"criterions": [
{
"exact_snippets": "ECOG performance status grade <=2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "grade",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* life expectancy >12 weeks;",
"criterions": [
{
"exact_snippets": "life expectancy >12 weeks;",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* adequate bone marrow reserve;",
"criterions": [
{
"exact_snippets": "adequate bone marrow reserve",
"criterion": "bone marrow reserve",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* adequate hepatic and renal function;",
"criterions": [
{
"exact_snippets": "adequate hepatic ... function",
"criterion": "hepatic function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate ... renal function",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* ability to comply with the protocol procedures (including geographic accessibility);",
"criterions": [
{
"exact_snippets": "ability to comply with the protocol procedures",
"criterion": "compliance with protocol procedures",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "geographic accessibility",
"criterion": "geographic accessibility",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* written informed consent.",
"criterions": [
{
"exact_snippets": "written informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "form",
"expected_value": "written"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* non-malignant systemic disease or conditions that precluded patients from receiving the study therapy;",
"criterions": [
{
"exact_snippets": "non-malignant systemic disease or conditions that precluded patients from receiving the study therapy",
"criterion": "systemic disease or conditions",
"requirements": [
{
"requirement_type": "malignancy",
"expected_value": false
},
{
"requirement_type": "impact on therapy",
"expected_value": "precludes receiving study therapy"
}
]
}
]
},
{
"line": "* second primary malignancies and previous systemic antineoplastic treatment including somatostatin analogues;",
"criterions": [
{
"exact_snippets": "second primary malignancies",
"criterion": "second primary malignancies",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "previous systemic antineoplastic treatment",
"criterion": "previous systemic antineoplastic treatment",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
},
{
"exact_snippets": "somatostatin analogues",
"criterion": "previous somatostatin analogue treatment",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
}
]
},
{
"line": "* history of prior malignancy, excepted for cured non-melanoma skin cancer, and cured in situ cervical carcinoma.",
"criterions": [
{
"exact_snippets": "history of prior malignancy",
"criterion": "prior malignancy",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
},
{
"exact_snippets": "cured non-melanoma skin cancer",
"criterion": "non-melanoma skin cancer",
"requirements": [
{
"requirement_type": "status",
"expected_value": "cured"
}
]
},
{
"exact_snippets": "cured in situ cervical carcinoma",
"criterion": "in situ cervical carcinoma",
"requirements": [
{
"requirement_type": "status",
"expected_value": "cured"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}